Movymia (Teriparatide)

Teriparatide is a synthetic fragment of parathyroid hormone that binds to the PTH1 receptor on bone‑forming cells called osteoblasts. This activation triggers signaling pathways that increase osteoblast activity, promote the production of bone matrix, and enhance mineralization, resulting in net bone gain.

The specific dose and dosing schedule for Movymia are determined by the prescribing healthcare professional based on the patient’s clinical condition, weight, and response to therapy. Only a qualified prescriber can set the appropriate regimen.

Safety of teriparatide in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the Movymia product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and import documentation.

Unlike anti‑resorptive agents such as bisphosphonates, Movymia is an anabolic therapy that actively builds new bone. This mechanism can lead to greater increases in bone mineral density, especially in patients with severe bone loss, but it is typically reserved for those who have not responded adequately to other treatments.

Movymia must be stored refrigerated at 2‑8 °C. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If the temperature rises above the recommended range, discard the product according to local regulations.

Movymia is given as a subcutaneous injection, usually in the thigh or abdomen. The injection is performed by a trained healthcare professional or the patient after proper instruction. The site should be rotated to minimize local irritation.

The most serious potential risks include the rare development of osteosarcoma, severe hypercalcemia, and serious allergic reactions such as anaphylaxis. Patients should be monitored regularly for signs of elevated calcium and any unexpected symptoms, and therapy should be stopped if serious adverse events occur.

Movymia is contraindicated in individuals with a history of skeletal malignancies such as osteosarcoma, those with hyperparathyroidism, or patients with unexplained hypercalcemia. It should also be avoided in patients who are allergic to teriparatide or any of the formulation excipients.